english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the October issue of Prescrire International: A public awareness campaign which mainly benefits companies

FREE DOWNLOAD The pharmaceutical company Abbvie, which markets adalimumab (Humira°), has jointly funded a public awareness campaign produced by the patient organisation France Psoriasis. Objective: marketing.
Full text available for free download.
1 October 2020

Hydroxychloroquine: the situation is critical

EDITORIALAccording to the methodological principles of clinical evaluation, comparative trials provide the most reliable evidence when evaluating treatments. The lowest-level evidence comes from expert opinions, case series, other observational studies and empiricism. This is still true in 2020 – and also in covid-19.
1 October 2020

Gentian violet used when breastfeeding: irritant and carcinogenic

Gentian violet has no place in the treatment of nipple thrush while breastfeeding, nor of oral thrush in the newborn baby.
1 October 2020

Pinworm infection: easy to detect and easy to treat

Anal itching at night is highly suggestive of pinworm infection, an intestinal parasitic infection that is very common in children. Several drugs, none of which have serious adverse effects, eradicate the parasites, after two doses, given two weeks apart.
1 October 2020

Proton pump inhibitors: increased risk of severe covid-19

 NEWS UPDATE  Proton pump inhibitors (PPIs) are known to increase the risk of various infections, including pneumonia and pseudomembranous colitis. What about covid-19 infection? A recent study yields some useful information.
15 September 2020

Covid-19 patients who are not hospitalised: anticoagulation is rarely justified

 NEWS UPDATE  The risk of thromboembolism in patients with a mild to moderate form of covid-19 is unclear and probably varies greatly between patients. Is anticoagulation justified to prevent deep vein thrombosis in patients with covid-19 who are not hospitalised?
24 September 2020

Cannabidiol (Epidyolex°) in certain severe forms of childhood epilepsy: an option to consider, but liver function must be monitored

FEATURED REVIEW Cannabidiol (Epidyolex°) has been granted marketing authorisation in the European Union for patients aged 2 years and older with Lennox-Gastaut syndrome or Dravet syndrome, in combination with antiepileptic treatment including at least clobazam. How do Prescrire's editors rate this treatment in this situation?
Full text (3 pages) available for download by subscribers.
1 September 2020

In the September issue of Prescrire International. VEGF inhibitors: arterial aneurysm and dissection

FREE DOWNLOAD Drugs that target vascular endothelial growth factor (VEGF) inhibit angiogenesis and are mainly used to treat diseases involving vascular proliferation, in particular cancer and certain eye conditions (by intravitreal administration). They can provoke cardiovascular disorders such as hypertension, heart failure and arterial or venous thromboembolic events.
Full text available for free download.
1 September 2020

Evidence required: for covid-19 too

EDITORIALAside from the covid-19 epidemic's many major public-health and economic consequences around the world, it has also raised questions for many people about drug evaluation and the need for evidence before using a drug to treat patients.
1 September 2020

Mild asthma: adapt treatment according to patients’ needs

An inhaled beta-2 agonist as needed, possibly combined  with an as-needed or continuous inhaled corticosteroid.
1 September 2020

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90